Health
“A woman named Megan Hancocks injected a black-market peptide to lose weight and developed acute liver failure within days." (Post text: "I injected a peptide to lose weight, my liver started failing just days later." Caption: "Her decision led to acute liver failure within days, and six months later, despite some recovery, her life has…”
Plain restatementAn Australian woman, Megan Hancocks, self-injected an unapproved product sold outside the regulated market and labelled as the weight-loss peptide retatrutide, and was hospitalised in acute liver failure a short time afterwards, with ongoing health problems about six months later.
General information only - not medical advice.
This one checks out in its essentials. Megan Hancocks is a real, named woman in Australia who told ABC News she bought a product labelled as the unapproved weight-loss peptide retatrutide, paying cash to a beautician, and injected it herself without medical advice in late December. She was hospitalised in acute liver failure less than a week after her second dose, was assessed for a possible liver transplant, and still had serious health problems six months later. Her case is not a one-off, as Victorian health authorities and Australia's medicines regulator have linked a cluster of acute liver injury hospitalisations to products sold under the retatrutide name. The one thing the post flattens is important: retatrutide is still in clinical trials and cannot be legally sold anywhere, so what she injected was a counterfeit or unverified product, and one tested vial from this market contained nearly double the dose on its label. Doctors have raised the possibility of a contaminated batch and were still testing the vials, so the exact substance that damaged her liver has not been publicly identified. In short, the story is accurate, and the main caveat is that the harm traces to an unregulated product of unknown contents rather than to a verified medicine.
[drifted from the evidence:] A woman [drifted from the evidence:] named Megan Hancocks [drifted from the evidence:] injected a black-market peptide [drifted from the evidence:] to lose weight and [drifted from the evidence:] developed acute liver failure [drifted from the evidence:] within days." (Post text: "I injected a [drifted from the evidence:] peptide to lose weight, my liver started failing just days later." Caption: "Her decision led to acute liver failure within days, and six months later, [drifted from the evidence:] despite some recovery, her life has been radically changed.")
[added by the neutral restatement:] An Australian woman, Megan Hancocks, [added by the neutral restatement:] self-injected an unapproved product sold outside the regulated market and labelled as the weight-loss peptide [added by the neutral restatement:] retatrutide, and [added by the neutral restatement:] was hospitalised in acute liver failure a [added by the neutral restatement:] short time afterwards, with ongoing health problems about six months later.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- A woman named Megan Hancocks is a real, named person in original ABC News reporting, not an anonymous or unverifiable figure.
- She obtained an unapproved product labelled as the peptide retatrutide outside regulated channels, paying cash to a beautician.
- She injected it herself without medical supervision, taking two doses four days apart.
- She was hospitalised in acute liver failure a short time afterwards and was assessed for a possible liver transplant.
- Six months later she still had significant ongoing health consequences, including skin reactions to treatment.
- The post attributes the account to Australia's ABC, which is the correct original source.
- The wider context is real: multiple Victorian hospitalisations, a state health alert, and TGA and Chief Medical Officer warnings about unapproved peptides.
- Omitted qualifier: the post says she "injected a peptide," which implies the product was what it claimed to be. The vials are counterfeit or unverified, retatrutide is not legally sold anywhere, and one tested vial contained nearly double the labelled concentration. The harm is tied to an unregulated product of unknown contents, not to a verified dose of a known drug.
- Minor temporal compression: "within days" is accurate relative to the second dose, but the full timeline is roughly ten to twelve days from the first injection. The headline wording "just days later" slightly tightens this.
- Unsupported causal inference risk in the framing, not in the facts: a single case plus a case cluster supports a strong signal and an official warning, but the post's phrasing invites readers to treat the causal mechanism as settled when doctors are still testing the product and have raised the possibility of a contaminated batch.
- Category breadth: the post's image text uses the generic word "peptide," which covers a very wide range of substances. The documented harm here concerns one specific category of counterfeit product sold under the retatrutide name.
- The exact substance or contaminant that caused her liver injury. Laboratory testing of the implicated vials was reported as ongoing.
- Whether any pre-existing condition, other medication, or co-exposure contributed. No such detail was located in the available reporting.
- The precise clinical severity grading and her current status as of late 2026. Reporting traced to mid-2026 follow-up at the six-month mark.
- The exact wording of the New York Post article itself, which was not retrieved directly. The assessment rests on the ABC original the post cites.
The named individual, the product, the timeline and the outcome all check out against the original ABC News reporting, which the Instagram post correctly credits. Megan Hancocks bought a drug labelled as the peptide compound retatrutide in cash from a beautician, and within a week of her second dose she was in acute liver failure. She hesitated for a while before injecting it because she did not have a doctor's advice and was unsure about dosage, but took her first dose on December 24 last year and a second dose on December 28. Less than a week later, she went to hospital and was found to be in acute liver failure. Liver transplant specialist Marie Sinclair, from the Victorian Liver Transplant Unit based at the Austin Hospital, first heard of Ms Hancocks when her treating doctors at the Royal Melbourne flagged her for potential liver transplant. She spent about a month at the Royal Melbourne Hospital in January but has been back in hospital multiple times since, and at one stage her doctor began discussing the prospect of a liver transplant. ABC described her as a woman who found herself in acute liver failure within a week of her second dose of the drug, with ongoing health issues six months later. She has also been suffering skin reactions to liver repair treatment, which matches the skin-reaction image in the post. Her case is not isolated. Senior doctors from a hospital in Melbourne's north warned people against taking drugs labelled as the experimental weight loss medication retatrutide after discovering multiple cases of liver damage and other serious illness. Six cases of acute liver toxicity were reported in Victoria in 2026, all linked to an unapproved peptide product labelled as retatrutide, and a seventh Victorian patient was later hospitalised for acute liver toxicity, with doctors concerned a possible contaminated batch might be to blame and testing underway on the counterfeit peptides linked to the liver failure cases. The product itself is not a legally available medicine. Eli Lilly states that retatrutide is an investigational molecule in Phase 3 trials, that it has not been reviewed or approved by the FDA or any regulatory agency in the world, and that no one can legally sell it for human use. A vial of black-market "retatrutide" provided to the ABC for testing returned nearly double the concentration listed on its label, prompting warnings about overdose risk.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.